Literature DB >> 15704289

COX-2 inhibitors: cancer prevention or cardiovascular risk?

Kathryn Senior.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15704289     DOI: 10.1016/s1470-2045(05)01720-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  Prostaglandin E2 enhances mitogen-activated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling.

Authors:  Li Zhang; Li Jiang; Qiuyan Sun; Tao Peng; Kexin Lou; Ningbo Liu; Jing Leng
Journal:  Mol Cell Biochem       Date:  2007-06-06       Impact factor: 3.396

2.  Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.

Authors:  Raghavendra Gowda; Subbarao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2012-10-30       Impact factor: 6.261

3.  Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density.

Authors:  Wei Tse Yang; Michael T Lewis; Kenneth Hess; Helen Wong; Anna Tsimelzon; Nese Karadag; Michelina Cairo; Caimaio Wei; Funda Meric-Bernstam; Powel Brown; Banu Arun; Gabriel N Hortobagyi; Aysegul Sahin; Jenny C Chang
Journal:  Breast Cancer Res Treat       Date:  2009-02-25       Impact factor: 4.872

Review 4.  Inflammatory Responses during Tumour Initiation: From Zebrafish Transgenic Models of Cancer to Evidence from Mouse and Man.

Authors:  Abigail Elliot; Henna Myllymäki; Yi Feng
Journal:  Cells       Date:  2020-04-20       Impact factor: 6.600

5.  Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer.

Authors:  Lilan Yi; Wei Zhang; Hongman Zhang; Jie Shen; Jingwen Zou; Peng Luo; Jian Zhang
Journal:  Drug Des Devel Ther       Date:  2018-08-07       Impact factor: 4.162

6.  Health-Beneficial Phenolic Aldehyde in Antigonon leptopus Tea.

Authors:  Vanisree Mulabagal; Ruby L Alexander-Lindo; David L Dewitt; Muraleedharan G Nair
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-20       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.